Note: This column describes the experiences of the author’s son with dupilumab. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Jonah, my son with epidermolysis bullosa (EB), and I just made another trip to Chicago right before Christmas. This…

I’ll always feel when the seasons are changing by the way my skin reacts. Here in Vienna, autumn is slowly coming to an end and winter is coming, slowly crawling into our smallest crevices. I not only recognize winter when it gets darker outside and the temperature drops, but I…

The skin is the body’s largest organ, with a total surface area of about 22 square feet. The skin protects us from microbes and the elements, helps regulate body temperature, and permits the sensations of touch, heat, and cold. In my case, my skin is “special.” I live with…

Researchers have developed a new technique that improves the efficiency of generating stem cells from patients with various diseases, including epidermolysis bullosa, with the goal of one day applying it in clinical use. Scientists already had developed methods by which cells from an adult donor can be “reprogrammed” to become stem…

Skin colonization by bacteria resistant to Bactroban (mupirocin) is frequent among patients with epidermolysis bullosa (EB), and may be due to home skin care practices, according to researchers at Columbia University. The finding was reported in the study “Wound culture isolated antibiograms and caregiver-reported skin…

Amicus Therapeutics, a company developing therapeutics for rare diseases, recently released an update of the company’s clinical trial testing SD-101 as a potential therapy for patients with epidermolysis bullosa. The company’s investigational drug SD-101 is a skin cream designed for the treatment of skin blistering and lesions, and it…

Cannabinoid therapy developer InMed and French tissue engineering company ATERA have teamed up to develop 3-D human skin models with tissue taken from epidermolysis bullosa (EB) patients. The models will be used to test InMed’s candidate therapy INM-750 in the lab before moving to clinical trials in…